Key Takeaways CHE shares sank 15% after Q4 EPS and revenues missed estimates, with margins contracting.Chemed's VITAS revenues rose 1.9%, while Roto-Rooter sales fell 3.7% y/y.CHE's gross margin shrank 181 bps and the 2026 EPS outlook of $23.25-$24.25 fell short of estimates. Chemed Corporation (CHE) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.42, which fell 6% year over year. The figure missed the Zacks Consensus Estimate by 8.55%.The company’s GAAP EPS was $6.02, up 2% from last y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period from ________ to________ Commission File Number: 1-8351 CHEMED CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati ...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Chemed Corporation (NYSE: CHE). The investigation focuses on Chemed’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Chemed securities? If you purchased Chemed securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.Or for more information, contact Jim Baker ...

Chemed (NYSE:CHE) Q4 2025 Earnings call February 26, 2026 10:00 AM ET Company ParticipantsHolley Schmidt - Vice President and Assistant ControllerJoanna Gajuk - Director of US Equity ResearchJoel Wherley - COOKevin McNamara - President and CEOMichael Witzeman - CFOConference Call ParticipantsBen Hendrix - AnalystBrian Tanquilut - Senior Equity Analyst and Healthcare Services Equity ResearchOperatorGood day, and thank you for standing by. Welcome to the Chemed Corporation fourth quarter 2025 earnings confere ...

Chemed (NYSE:CHE) Q4 2025 Earnings call February 26, 2026 10:00 AM ET Company ParticipantsHolley Schmidt - Vice President and Assistant ControllerJoanna Gajuk - Director of US Equity ResearchJoel Wherley - COOKevin McNamara - President and CEOMichael Witzeman - CFOConference Call ParticipantsBen Hendrix - AnalystBrian Tanquilut - Senior Equity Analyst and Healthcare Services Equity ResearchOperatorGood day, and thank you for standing by. Welcome to the Chemed Corporation fourth quarter 2025 earnings confere ...

Financial Data and Key Metrics Changes - VITAS' net revenue for Q4 2025 was $418.8 million, a 1.9% increase compared to the prior year, driven by a 1.3% increase in days of care and a 2.2% increase in Medicare reimbursement rates [12] - Adjusted EBITDA for VITAS, excluding Medicare cap, was $91.6 million, a decline of 1.7% year-over-year, with an adjusted EBITDA margin of 21.7%, down 79 basis points from the prior year [13] - Roto-Rooter revenue declined by 3.7% in Q4 2025 compared to the same period in 2024, with adjusted EBITDA at $47.5 million, a decrease of 21.1% [8][18] Business Line Data and Key Metrics Changes - VITAS admissions totaled 17,419 in Q4 2025, a 6% improvement from Q4 2024, with hospital-directed admissions increasing by 9.9% [4][23] - Roto-Rooter branch residential revenue decreased by 3.1%, while branch commercial revenue increased by 1.6% [8][14] - Water restoration revenue declined by 10.3%, attributed to increased scrutiny from insurance companies leading to higher write-offs [15][17] Market Data and Key Metrics Changes - The percentage of total admissions from hospitals in Florida was 44.8%, indicating a recovery in the patient mix post-pandemic [5] - Average revenue per patient day for VITAS was $288.01, an increase of 86 basis points from the prior year [13] - The average daily census for VITAS was 22,462 patients, a 1.3% increase, with a median length of stay of 17 days [23] Company Strategy and Development Direction - VITAS is focusing on balancing admissions between hospital-based and other pre-admission locations to improve revenue growth and EBITDA margins [6][24] - Roto-Rooter is expanding its commercial business by hiring commercial business managers, which has shown positive preliminary results [8][17] - The company plans to pursue strategic acquisitions and new start opportunities in Florida and other CON states to drive growth [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the Florida Medicare cap issue is resolved, allowing for a return to normal growth patterns for VITAS [10][26] - Roto-Rooter is expected to face a challenging operating environment but anticipates modest growth driven by improved lead generation and billing practices [10][11] - The company expects 2026 to be a transition year for both subsidiaries, with VITAS revenue growth projected at 5.5%-6.5% and Roto-Rooter at 3%-3.5% [19][20] Other Important Information - The company repurchased 400,000 shares of Chemed stock at an average price of $436.39, funded by free cash flow from both subsidiaries [18] - The estimated Medicare cap billing limitations for 2026 are $9.5 million, significantly lower than $27.2 million in 2025 [19] Q&A Session Summary Question: What gives confidence in Roto-Rooter revenue growth in 2026 after flat revenues in 2025? - Management highlighted improvements in paid leads and a recovery in natural leads visibility, which are expected to drive revenue growth [30][34] Question: Are the long-term margin targets still achievable for Roto-Rooter? - Management indicated that achieving 24%-25% margins is still possible if Roto-Rooter can return to normalized revenue growth [42][44] Question: What is the outlook for VITAS revenue and EBITDA progression in 2026? - Management expects a return to normalized growth rates of 7%-9% as the patient mix is adjusted, with revenue growth building throughout the year [49][50]

CONTACT: Michael D. Witzeman (513) 762-6714 Chemed Reports Fourth-Quarter 2025 Results CINCINNATI, February 25, 2026—Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2025, versus the comparable prior-year period. VITAS Results for Qua ...

CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2025, versus the comparable prior-year period. Results for Quarter Ended December 31, 2025 Consolidated operating results: Revenue was $639 ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - Chemed Corporation's Board of Directors has authorized an additional $300 million for stock repurchase under the existing share repurchase program, funded through operational cash and a revolving credit facility [1] - The company declared a quarterly cash dividend of 60 cents per share, payable on March 13, 2026, to shareholders of record as of February 23, 2026, marking the 219th consecutive quarterly dividend in its 54 years as a public company [2] - Chemed operates two wholly owned subsidiaries: VITAS Healthcare, the largest provider of end-of-life hospice care in the U.S., and Roto-Rooter, the leading provider of plumbing and drain cleaning services [3]